Feng-Zhu Zheng

Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

Fanghui Zhao, Ting Wu, Yuemei Hu et al. · The Lancet Infectious Diseases · 2022 · 89 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial

Fengcai Zhu, Guo‐Hua Zhong, Weijin Huang et al. · The Lancet Infectious Diseases · 2023 · 41 citations

Veterinary Medicine, Immunology, Immunization +10

Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial

Yuemei Hu, Zhaofeng Bi, Ya Zheng et al. · Science Bulletin · 2023 · 26 citations · Full text

Veterinary Medicine, Immunology, Oncology +17

Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial

Kai Chu, Zhaofeng Bi, Weijin Huang et al. · The Lancet Regional Health - Western Pacific · 2023 · 13 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17